Effect of the adjuvant therapy with bronchoalveolar lavage in treatment of children with refractory mycoplasma pneumonia

  • CHEN Lijuan ,
  • YUAN Xia ,
  • LIU Qingqing
Expand
  • Department of Pediatrics, No.990 Hospital, Joint Logistics Support Force of the Chinese People's Liberation Army, Zhumadian 463000, China

Received date: 2022-10-27

  Online published: 2023-09-22

Abstract

Objective: To analyze the effect of the adjuvant therapy with bronchoalveolar lavage, pulmonary surfactant protein,lactate dehydrogenase (LDH), penetrating hormone 3 (PTX3) level, and arterial blood gas indexes in children with refractory mycoplasma pneumonia (RMPP). Methods: Clinical data of 97 children with RMPP in our hospital from October 2016 to June 2022 were collected retrospectively, and divided into the drug treatment group (48 cases) and bronchoalveolar lavage group (49 cases) according to the different treatment methods. The children in the drug treatment group were treated with macrolide for anti-infection and symptomatic treatment. The children in the bronchoalveolar lavage group were treated with bronchoscopic bronchoalveolar lavage on the basis of the drug treatment group. The curative effect, the levels of pulmonary surfactant protein A (SP-A), pulmonary surfactant protein D (SP-D), LDH and PTX3 and arterial blood gas indexes before and after treatment of the two groups were compared. Results: The total effective rate in the bronchoalveolar lavage group was 89.80 %, which was obviously higher than that in the drug treatment group (70.83 %) (P<0.05). Before treatment, the levels of SP-A, SP-D, LDH, PTX3 and arterial blood gas indexes had no significant difference between the two groups (P>0.05). After treatment, the levels of SP-A, SP-D, LDH and PTX3 in the bronchoalveolar lavage group were obviously lower than those in the drug treatment group, and the arterial blood gas indexes were obviously better than those in the drug treatment group (P<0.05). The incidence of adverse reactions in the bronchoalveolar lavage group (10.00 %) was obviously lower than the drug treatment group (26.00 %) (P<0.05). Conclusion: The adjuvant therapy with bronchoalveolar lavage in the treatment children with RMPP has a good treatment effect, which could significantly improve the arterial blood gas indexes and lower the levels of pulmonary surfactant protein (SP-A, SP-D), LDH and PTX3 with high safety.

Cite this article

CHEN Lijuan , YUAN Xia , LIU Qingqing . Effect of the adjuvant therapy with bronchoalveolar lavage in treatment of children with refractory mycoplasma pneumonia[J]. Journal of Baotou Medical College, 2023 , 39(9) : 70 -73 . DOI: 10.16833/j.cnki.jbmc.2023.09.014

References

[1] 张天骄,刘盈盈,裴亮. 儿童肺炎支原体肺炎并发坏死性肺炎的临床预测因素[J].中国医科大学学报,2022,51(1): 79-82.
[2] 何雯,张琪,刘文君,等. 大环内酯类抗生素联合纤支镜肺泡灌洗治疗难治性肺炎支原体感染患儿的临床疗效[J].药学服务与研究,2021,21(4): 257-261,283.
[3] 中华医学会儿科学分会呼吸学组,中华实用儿科临床杂志·编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J].中华实用儿科临床杂志,2015,17(30): 1304-1308.
[4] 岑敏,秦人豪,王海风. 肺炎支原体肺炎儿童血清miR-16的表达水平及其对肺炎支原体免疫的作用[J].东南大学学报(医学版),2022,41(3): 345-351.
[5] Tsai TA,Tsai CK,Kuo KC,et al. Rational stepwise approach for mycoplasma pneumoniae pneumonia in children[J].J Microbiol Immunol Infect,2021,54(4): 557-565.
[6] 高枫. 纤支镜支气管灌洗对儿童难治性肺炎支原体肺炎临床症状、炎症因子水平的影响[J].系统医学,2022,7(9): 10-14.
[7] 梁丹丹,纵书芳. 小儿难治性肺炎支原体肺炎肺泡灌洗液SF、SP-A、SP-D变化及其对治疗效果预测价值[J].临床误诊误治,2021,34(11): 92-96.
[8] 郑雪香,林继雷,代继宏. 基于决策曲线和剂量反应分析评估乳酸脱氢酶对儿童难治性肺炎支原体肺炎的预测价值[J].中国当代儿科杂志,2020,22(2): 112-117.
[9] 曹芳,方识进,华山,等. 电子纤维支气管镜保留灌注乙酰半胱氨酸及布地奈德治疗儿童难治性支原体肺炎的临床效果观察[J].中国医药,2020,15(3): 369-373.
Outlines

/